A&G Pharmaceutical, Inc.

A&G Pharmaceutical, Inc., operating under the doing-business-as name Precision Antibody, is a for-profit manufacturer of biological research materials and custom antibody development services headquartered in Columbia, Maryland. The company has maintained federal contracting relationships for over two decades, establishing itself as a specialized supplier of critical reagents and biological materials that support federal biomedical research initiatives. Precision Antibody focuses on providing custom antibody development, monoclonal and polyclonal antibody production, cell line generation, antibody labeling, and laboratory testing services to support diverse research areas including oncology, infectious disease, neurodegenerative disease, and drug development programs.

The company's federal contract award history demonstrates a consistent focus on providing specialized biological materials and custom antibody development services to the National Institutes of Health and its component agencies. Primary funding agencies for A&G Pharmaceutical's contract awards include the National Center for Advancing Translational Sciences (NCATS) and the National Institute of Allergy and Infectious Diseases (NIAID), both of which operate under the Department of Health and Human Services. Recent awards include a September 2025 purchase order from NCATS valued at $13,600 for generating reagents against AZM-152, a March 2025 purchase order from NIAID for $16,900 to prepare monoclonal antibodies against the MARCH1 protein, and an August 2024 NIAID contract for $18,500 covering laboratory testing, fusion, and cloning services. Historical awards showcase delivery orders under a DOK7 contract vehicle with NCATS, including a March 2024 delivery order for $105,669.50 supporting Task Order 7 for custom antibody development services and a September 2023 delivery order valued at $132,862.50 for generating monoclonal cell lines and labeled monoclonal antibodies against human and mouse collagen Q. Additional past awards include a June 2022 NCATS delivery order for $107,461.88 for polyclonal rat antibody and monoclonal rat antibodies against glycol-chitosan nanoparticles, and various NIAID purchase orders dating back to 2021. All identified contract awards were awarded without set-aside designations through open competition, reflecting the company's competitive positioning in the federal marketplace.

A&G Pharmaceutical maintains a single-award Blanket Purchase Agreement with the NIH Office of Logistics and Acquisition Operations valued at $10,000,000, effective from January 30, 2024 through January 31, 2026. This BPA serves as the primary vehicle enabling the company to provide biological materials, laboratory and testing services, and animal testing services to multiple components of the National Institutes of Health as well as the U.S. Department of Agriculture's Agricultural Research Service. The agreement covers the development of custom monoclonal and polyclonal antibodies, cell line generation, antibody labeling, and specialized laboratory testing across multiple therapeutic and research domains. Task orders issued under this BPA framework have funded specific initiatives at NCATS, including work on DOK7 protein targets and various translational science projects, positioning A&G Pharmaceutical as a strategic partner for federal biomedical research infrastructure and reagent development.

Precision Antibody service rapidly develops customized, high-affinity monoclonal & polyclonal antibodies to your target antigen. We also offer both in vivo and in vitro monoclonal antibody production, from pilot scale to large-scale manufacturing.